BEVERLY, MA--(Marketwire - June 23, 2010) - Cellceutix Corporation (
Neonatal serotonin depletion and decreased brain plasticity are established observations in the autistic brain. The Cellceutix team has identified a reliable animal model and has been successful in chemically inducing these characteristics in the model. The data collected to this point has been promising as KM-391 has shown to be successful in altering the serotonin and brain plasticity levels resulting in physical and behavioral changes in the model that are similar to the "non-autistic" control groups.
The latest research involved physical measurements of serotonin levels in the cerebral cortex, hippocampus, and caudate nucleus areas of the brain. Several groups of rats were established with two of the groups being injected to induce the symptoms of autism. After 48 days, the brains were assayed for serotonin by ELISA with the data showing that the administration of KM-391 significantly increased serotonin levels in all 3 regions of the brain: cerebral cortex, hippocampus, and caudate nucleus, from very low levels as observed with the induced autism to normal levels as observed in placebo treated control which received no treatment. More detailed information on the research is available at www.cellceutix.com.
George Evans, Cellceutix Chief Executive Officer, commented, "This new data is highly relevant as it reinforces the data from previous studies and further solidifies our contention that serotonin levels in multiple brain regions may be a necessary key to the next generation of autism treatments."
About Cellceutix
Cellceutix Corporation is a preclinical cancer, autism and anti-inflammatory drug developer. Cellceutix owns the rights to eight drug compounds, including Kevetrin™, which it is developing as a treatment for drug-resistant cancers, and KM-391, which it is developing for the treatment of autism. More information is available on the Cellceutix web site at www.cellceutix.com.
This Press Release contains forward-looking statements that are based on our current expectations, beliefs and assumptions about the industry and markets in which Cellceutix Corporation operates. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause Cellceutix's actual results to be materially different from any future results expressed or implied by these statements. Actual results may differ materially from what is expressed in these statements, and no assurance can be given that Cellceutix can successfully implement its core business strategy and improve future earnings.
The factors that may cause Cellceutix's actual results to differ from its forward-looking statements include: Cellceutix's current critical need for additional cash to sustain existing operations and meet ongoing existing obligations and capital requirements; Cellceutix's ability to implement its new product development and commercialization, enter into clinical trials, expand the intellectual property portfolio, and receive regulatory approvals in a timely and cost-effective manner. All forward-looking statements are also expressly qualified in their entirety by the cautionary statements included in Cellceutix's SEC filings, including its quarterly reports on Form 10-Q and its annual report on Form 10-K.
Kevetrin and KM-391 have not been studied in humans at this time. The Company's positive results in animal studies do not necessarily guarantee success in humans, though they may form the basis for beginning Phase 1 trials.
Contact Information:
Contact:
Cellceutix Corp.
Leo Ehrlich
CFO
(978) 633-3623